Pharmafile Logo

Living with NASH: An Unexpected Diagnosis

Published in eyeforpharma November 2017 by Mariel Metcalfe

With no current licensed treatments and more than 20 compounds in phase II and III, the liver disease non-alcoholic steatohepatitis (NASH) represents a huge opportunity for pharma companies – if they understand patient needs.

As our waistlines thicken and our activity levels decrease, another chronic illness threatens to disturb our comfortable lifestyles. And, because it’s relatively unknown, diagnosis comes as a shock to patients, who usually associate liver disease with heavy consumption of alcohol…

Read the full article: https://www.researchpartnership.com/news/2017/11/living-with-nash-an-unexpected-diagnosis/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Webcast:

UX beyond the website: Insights for the age of omnichannel

News:

MedTech Qualitative Specialist joins Research Partnership

Guide

How to embrace behavioural science principles in healthcare MR

Article

A glimmer of hope for Alzheimer’s patients, but at what cost?

Video

Virtual Conference Live

Report

Digital Health Tools - Physician Trends

Webcast

Oncology landscape: How innovative market research methods can navigate you to success

Article:

The disparity of patient experiences with Crohn’s Disease in Europe and Japan

Research Partnership’s MedTech Division appoints two Directors

Chris Carles has joined as a Director in our Philadelphia office and Andrew Way as a Research Director in our UK office.

Webcast: Influencing HCP behaviours – Is now the perfect opportunity?

Putting behavioural science at the forefront of market research